TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- EmergConnect’s digital platform helps hospitals cut ER triage time by up to 60%.

The Trader’s Mind bridges the gap between strategy and success, offering tools like trading journals, breathing techniques, ...

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for ...

In addition to sickle cell disease, rilzabrutinib has received orphan drug designation for immune thrombocytopenia (ITP) in the US, the EU, and Japan, for warm autoimmune hemolytic anemia (wAIHA) in ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line ...

The full invitation to the AGM 2025 may be found in the General Meetings section of the Company’s website here.

Under the terms of the agreement, DentPrime will serve as an official sponsor of Orli Znojmo throughout the 2025 season, ...

Elite Clinical Network (ECN), a fully-integrated clinical research site network, has appointed Christopher (“Chris”) Brennan ...

Agenda and keynote details now available for the premier annual event advancing health data sharing, health improvement, and ...

Nxera previously announced the initiation of the Phase 3 registrational program of NBI-’568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...